Trial Profile

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DB-001 (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection
Focus Therapeutic Use
Acronyms EXIT COVID-19
Sponsors Direct Biologics

Most Recent Events

12 Jul 2023 According to a Direct Biologics media release, results were published in the June 2023 edition of the peer-reviewed medical journal CHEST.
12 Jul 2023 Results published in a Direct Biologics Media Release.
14 Mar 2023 According to a Direct Biologics media release, On review by an independent data safety monitoring board (DSMB), no AEs or SAEs were determined to be related to ExoFlo.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com